TER — Teradyne, Inc.

The Street is constructive: 19 Buy/12 Hold ratings, consensus target $461.50, and recent targets as high as $550. The Q2 2026 beat (revenue $1.33B, non-GAAP EPS $2.47 vs. consensus by $0.38) and management's note that AI-driven apps are >60% of revenue, with compute test revenue +600% YoY, have kept sentiment positive. However, the stock is down 5.7% over the past month and 5.8% over three months as valuation concerns and cyclicality temper enthusiasm.

The 3-year trend shows a clear inflection, not a blip. Revenue was range-bound around $600–750M per quarter through 2024 and early 2025 (e.g., Q2 2025: $651.8M). Then Q4 2025 jumped to $1.083B, Q1 2026 to $1.282B, and Q2 2026 to $1.329B—roughly doubling YoY. Operating margin expanded from 13.9% in Q2 2025 to 32.9% in Q2 2026; EPS rose from $0.49 to $2.38 over the same period. FCF is supporting the trend: TTM FCF ~$800M, with Q2 2026 FCF of $378M. The only weak spot was Q3 2025 FCF of $2.4M, but that recovered sharply. This looks like a structural AI-driven acceleration, though it remains early and cyclical.

As of 2026-09-13, TER is not cheap. TTM P/E is 51.8x vs. a 5-year average of 35.1x; P/S is 13.3x vs. a 5-year average of 6.9x. On FY2026 EPS estimate of $9.207, forward P/E is ~41.2x. The PEG ratio of 0.337 looks low, but it relies on an unsustainable hyper-growth rate. Against its own history, the stock is rich; against the sheer AI-driven earnings inflection, it's expensive but not irrational. Rich vs. its own history is the right label.

The market is pricing in continued AI-driven growth. FY2025 diluted EPS was ~$3.48; FY2026 consensus is $9.207, implying ~165% growth. Q2 2026 EPS alone was $2.38, and Q3 2026 guidance is $1.79–$2.09. If Q3 (due Oct. 27, 2026) delivers sequentially, the forward multiple compresses quickly. But at 51.8x trailing earnings, any guidance wobble could trigger a sharp de-rating because expectations are already elevated. The playbook: watch Q3 guidance and AI compute test order trends; the stock needs execution, not just narrative.

As of 2026-09-13, RSI is 53.1 (neutral), and price is above its 20-day (+1.88%), 50-day (+3.8%), and 200-day (+18.45%) SMAs. The 1-week return is +6.36%, but 1-month is -5.72% and 3-month is -5.82%, so this is a rebound within a recent pullback, not a breakout. The long-term trend is still up, but momentum is mixed. Entry timing: neutral; better to wait for a pullback toward the 50-day SMA or post-Q3 confirmation.

• AI semiconductor capex supercycle: test intensity has risen from ~4% of wafer fab equipment spend in 2023 to ~8% in 2026, directly benefiting Teradyne's compute test platforms.
• Semiconductor cyclicality: test equipment remains historically boom-bust; the current AI-driven surge could normalize if AI capex slows.
• US–China trade restrictions and geographic concentration: high Taiwan/China exposure leaves TER vulnerable to export controls and supply-chain disruptions.
• Industrial automation/robotics recovery remains uneven, with cautious global industrial capex limiting the robotics segment.
• High beta (1.778) and elevated valuation make the stock sensitive to interest-rate expectations and growth-stock rotation.

• Q3 2026 earnings on Oct. 27, 2026: guidance is $1.20–$1.30B revenue and GAAP EPS $1.79–$2.09; a beat/raise could support the premium multiple.
• Continued UltraFLEXplus deployment for AI GPUs/ASICs and further upward EPS revisions if compute test demand accelerates.
• Potential recovery in the robotics/industrial automation segment.
• New analyst target hikes (e.g., Cantor Fitzgerald $550, BofA $525) if AI momentum persists.

• Valuation risk: 51.8x TTM P/E and 13.3x P/S vs. 5-year averages of 35.1x and 6.9x; any guidance miss could cause a sharp de-rating.
• Cyclicality: semiconductor test spending can reverse quickly; the current AI boom may not be linear.
• Geographic concentration: Taiwan/China exposure and tightening US–China export controls.
• Robotics segment weakness could persist if industrial capex stays soft.
• Customer concentration and potential order lumpiness in high-end test equipment.

Teradyne is a high-quality, debt-free AI test equipment leader in the middle of a dramatic earnings inflection. The balance sheet is pristine (no long-term debt, current ratio 2.1), FCF is strong (~$800M TTM), and AI compute test demand is real. But the stock is not cheap: it trades at 51.8x trailing earnings and rich versus its own history. The risk/reward remains favorable for long-term holders, but the easy money from the initial AI re-rating has been made. I'd be a selective buyer on pullbacks rather than chase at $379.72. This is analysis, not personalized financial advice.

I applied a ~40x P/E to an estimated FY2027 EPS of ~$10.95, built from the FY2026 consensus EPS of $9.207 plus ~20% growth and modest margin expansion. The 40x multiple is a premium to the 35.1x 5-year average, justified by the debt-free balance sheet and AI-driven test demand, but below the current ~41x forward P/E. This yields ~$438.